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Abstract 
 
 Our work’s aim was to explore mechanisms that could explain how the chemical 
inhibition of heat-shock protein 90 reduces NGF (nerve growth factor) signaling in rat 
pheochromocytoma PC12 cells. Geldanamycin is an antibiotic originally discovered based on 
its ability to bind heat-shock protein 90. This interaction can lead to the disruption of heat-
shock protein 90-containing multimolecular complexes. It can also induce the inhibition or 
even degradation of partner proteins dissociated from the 90 kDa chaperone and, eventually, 
can cause apoptosis, for instance, in PC12 cells. Before the onset of initial apoptotic events, 
however, a marked decrease in the activity of extracellular signal-regulated kinases ERK 1/2 
(extracellular signal-regulated kinase 1 and 2) and protein kinase B/Akt can be observed 
together with reduced expression of the high affinity nerve growth factor receptor, 
tropomyosine-related kinase, TrkA (tropomyosin receptor kinase, frequently: tropomyosin-
related kinase), in this cell type. The proteasome inhibitor MG-132 can effectively counteract 
the geldanamycin-induced reduction of TrkA expression and it can render TrkA and ERK1/2 
phosphorylation by nerve growth factor again inducible. This latter effect was not observed in 
the case of protein kinase B/Akt. The altered intracellular distribution of TrkA that we have 
found in geldanamycin-treated and proteasome-inhibited PC12 cells may, at least partially 
explain why nerve growth factor remains without effect on protein kinase B/Akt in this case. 
The lack of protein kinase B/Akt stimulation by nerve growth factor in turn reveals why nerve 
growth factor treatment can’t save PC12 cells from geldanamycin-induced programmed cell 
death. Our observations can help to better understand the mechanism of action of 
geldanamycin, the derivative compounds of which possess strong human therapeutical 
potential. 
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Introduction 
 
Geldanamycin and the Hsp90 
 
 Geldanamycin is a member of the ansamycin antibiotic family originally discovered in 
Streptomyces bacteria. Heat-shock protein 90 (Hsp90), an abundantly expressed, 
homodimeric, ATP-dependent molecular chaperone was identified as a geldanamycin target 
by means of affinity chromatography. As part of multimolecular complexes Hsp90 maintains 
a number of proteins, including signaling kinases, in their functionally correct conformation. 
The Hsp90 based complexes can bind a high variety of substrate proteins, the most 
widely known are the steroid receptors (which are released form the chaperone complex after 
the ligand binding and nuclear translocation of the hormone-receptor complex), and protein 
kinases participating in various signaling processes. Among these, based on cell type, the 
members of the ERK cascade are also found. Publications mention for example the Ras, Raf, 
and MEK proteins. The protein kinases are generally binding to the N-terminal binding site of 
the Hsp90 with their catalytic domain. The p23 and CDC37/p50 are essential members of the 
Hsp90 complexes formed this way.  
Ansamycin antibiotics can efficiently compete with, and hence inhibit the ATP 
binding of 90 kDa chaperones. The resulting disruption of heat-shock protein and chaperone 
function can cause the dissociation of Hsp90-containing complexes, or it can alter their 
intracellular localization even compromising their stability. Binding of geldanamycin and its 
derivatives to Hsp90 can shift it from a refolding chaperone to one that promotes the 
degradation of client proteins inside Hsp90-containing complexes. Hsp90 is also capable of 
passive, ATP/ADP-independent chaperoning.  
 
The Ras-ERK and protein kinase B/Akt signaling pathways in PC12 cells 
 
 The PC12 rat pheochromocytoma cell line is a popular model system to study nerve 
cell differentiation and survival in vitro. In serum-containing culturing medium PC12 cells do 
not require nerve growth factor (NGF) for survival, but upon addition of it they develop a 
sympathetic neuron-like phenotype. After binding to its ligand, TrkA trans-
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/autophosphorylation and activation elicits prolonged activation of the ERK-cascade in PC12 
cells, leading to differentiation. 
Upon the binding of the ligand, the high affinity TrkA NGF receptor goes through 
dimerization and consequently creates phosphotyrosine binding sites on itself for signaling 
proteins possessing SH2 domains by its tyrosine protein kinase activity. As a result of this 
process multiple signaling ways are started, one of them is launched as adapter proteins (e.g. 
Shc and Grb2) activate a guanine nucleotide exchange factor (Sos) (Figure 1.). This protein 
turns on Ras, the G protein anchored to the inner surface of the cell membrane, the 
inactivation of which requires the operation of the GTPase activating protein or GAP. It helps 
Ras to hydrolyze its bound GTP back to GDP. Before this can happen, Ras, in its GTP bound, 
active state induces a chain of protein kinases phosphorylating each other, the ERK cascade, 
which belongs to the group of MAPK cascades. Its consecutive members are Raf (a 
MAPKKK), MEK (which belongs to the class of MAPKKs), and finally ERK (extracellular 
signal-regulated kinase). This latter phosphorylates target proteins in the cytoplasm, and is 
also translocated into the nucleus where it can activate transcription factors such as the Serum 
Response Factor and Ternary Complex Factor. As a result of this ERK enzymes induce gene 
expression changes promoting differentiation by influencing transcription. The prompt 
activation of early- followed by the induction of late response genes leads ultimately to 
phenotype changes like sympathetic neuronal differentiation.  
TrkA has been shown to interact with Hsp90 in human neuroblastoma, and also in 
acute leukaemic cells. After the withdrawal of trophic factors the machinery of programmed 
cell death is activated in PC12 cells, whereas NGF stimulation of its cognate receptor 
tropomyosin-related kinase (TrkA) and its downstream indirect effector protein kinase B/Akt 
can inhibit apoptosis (Figure 1.). Along this pathway the activated TrkA stimulates the 
phosphatidylinositol 3-kinase enzyme, which catalyzes the production of a multi-
phosphorylated lipid derivative, phosphatidylinositol trisphosphate (PIP3), from 
phosphatidylinositol bisphosphate (PIP2). This will lead to the phosphorylation and activation 
of PKB/Akt, which is one of the most important factors for promoting cell survival.  
Depending on the examined cell type the result of geldanamycin treatment can be 
differentiation or programmed cell death. Apoptosis of PC12 cells, for example, can be 
induced by geldanamycin. Interestingly, this phenomenon could still be observed when NGF 
was present during geldanamycin treatment. 
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Figure 1.: General scheme of the ERK cascade and the PKB/Akt pathway. GAP: GTPase 
activating protein. Shc, Grb2: adapter proteins. Sos: a guanine nucleotide exchange 
factor. Ras: a monomeric G protein. Raf, MEK (MAPK/ERK kinase), ERK 
(extracellular signal-regulated kinase), PKB/Akt (protein kinase B), PDK1 
(phosphoinositide-dependent kinase 1), mTOR (mammalian target of rapamycin): 
protein kinases. SRE: serum responsive element = an enhancer. SRF: serum 
responsive factor = a transcription factor. TCF: ternary complex factor = the cofactor 
of SRF. PI3K: phosphatidylinositol 3-kinase: a lipid kinase. PIP3: 
phosphatidylinositol trisphosphate, a lipid-type second messenger molecule, 
generated from PIP2 (phosphatidylinositol bisphosphate). PTEN: phosphatase and 
tensin homolog: a lipid phosphatase. 
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Objectives 
 
In our work we have set out to identify mechanisms that could explain how 
geldanamycin treatment could interfere with NGF signaling via TrkA. In our PC12 cells 
treated with geldanamycin we aimed to study:  
- the changes in the level of the high affinity NGF receptor TrkA, as an Hsp90 client 
protein, and the effects of these on the protein kinase B/Akt and ERK1/2 signaling 
pathways;  
- the possible dissociation of Hsp90 complexes containing TrkA; 
- the influence of the MG-132 proteasome inhibitor on the changes of TrkA 
concentration; 
- the possibility of activating protein kinase B/Akt during treatments with 
geldanamycin combined with MG-132, so we could find an explanation for the 
apoptotic consequences of geldanamycin treatment;  
- the difference of TrkA intracellular localization compared to untreated cells, which 
could explain the alteration of signaling processes;  
- our work group further analyzed the inducing effect of the proteasome inhibitor on 
ERK1/2 phosphorylation.  
 
Materials and methods 
 
Reagents 
 All chemicals used were from Sigma-Aldrich (Budapest, Hungary) unless stated 
otherwise. NGF was purchased from Alomone Labs (Jerusalem, Israel). 
Tissue culture 
 PC12 rat pheochromocytoma cells (kindly provided by G.M. Cooper) passage number 
5 to 15) were plated onto plastic Petri dishes or Thermanox (Nalgene Nunc International, 
Rochester, NY, USA) coverslips (at 50% or 30% confluence, respectively) and maintained in 
DMEM complemented with 10% horse and 5% fetal bovine serum, for 24 hours to achieve 
sufficient adhesion. The cultures were kept at 37 °C in a humidified atmosphere containing 
5% CO2. Next day the media were switched to 0.5 % horse serum-containing DMEM for 24 
hours to silence growth factor-stimulated pathways before and during treatments. 
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Immunoprecipitation and Western blotting 
 After treatment the cultures were collected in ice-cold lysis buffer (50mM Tris-base, 
pH 7.4, 150 mM NaCl, 10% glycerol, 1 mM EGTA, 1 mM Na-orthovanadate, 5 µM ZnCl2, 
100 mM NaF, 10 μg/ml aprotinin, 1 µg/ml leupeptin, 1 mM PMSF, 1% Triton X-100) and 
frozen at -20 °C. Thawed samples were homogenized by vortexing for 20 seconds. The 
homogenate was centrifuged at 40,000 x g at 4 °C for 30 minutes and the protein 
concentration of the supernatant was determined (Lowry’s method, Detergent Compatible 
Protein Assay Kit, Bio-Rad, Hercules, CA, USA). For caspase-3 activity measurements cells 
were lysed in Chaps cell extract buffer and processed as suggested by the antibody supplier 
(Cell Signaling Technology, Beverly, MA, USA). 
For immunoprecipitation equal amounts of the samples (0.5 mg) were brought to 0.5 
μg/μl by the addition of lysis buffer and immunoprecipitated with 1 μg of anti-TrkA antibody 
(R&D Systems, Minneapolis, MN, USA) under gentle rotation for 2 hours. Next, the 
precipitates were collected with Protein A/G PLUS-Agarose (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) and washed according to the manufacturer’s instructions. Conditions 
to minimize nonspecific Hsp90 contamination of the precipitates were adjusted as described 
in our previously published work. 
Samples prepared from equal amounts of protein (see immunoprecipitates above or for 
Western blotting 50 μg in case of TrkA and 25 μg for the rest) were mixed with Laemmli 
buffer (the 4x stock contained 25 ml 1M Tris-HCl, pH 6.8, 40 ml glycerol, 8 g SDS, 10 ml 
100 mM EDTA, 10 ml 100 mM EGTA and 1 ml 1% bromophenol blue brought up to 100 ml 
with distilled water) and denatured by boiling. Subsequently, they were loaded onto 10% (or 
7,5 % for TrkA and 18% for cleaved caspase-3) SDS-containing polyacrylamide gels and 
separated based on molecular size. The gels were electro-blotted onto PVDF membranes 
(Hybond-P, GE Healthcare, United Kingdom). 
Immunological detection of the protein of interest was carried out by first blocking the 
membrane in 3% nonfat dry milk in TBS-Tween (10mM Tris-base, 150mM NaCl, 0.2% 
Tween-20, pH 8.0), followed by addition of the primary antibody [Phospho-p44/42 MAP 
Kinase to detect phospho-ERK1/2, anti-Akt and phospho-Akt (Ser 473) beta-Actin and 
phospho-TrkA (Tyr490), cleaved caspase-3 (Asp175), (Cell Signaling Technology), ERK-1 
(C-16), or ERK-2 (C-14), Trk (C-14), Hsp90 (Santa Cruz Biotechnology)] diluted in the 
blocking solution and incubated overnight. Antisera were diluted 1:1000. At this dilution rate 
methodical control samples prepared from antigen-deficient (nnr5) cells’ lysates (for anti-
TrkA and anti-phospho-TrkA), or by the omission of the primary antibodies (in all cases) 
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produced no specific immune signal expected at the right molecular weight range in pilot 
experiments. Excess antibody was removed by five washes of TBS-Tween. Membranes were 
incubated with a horseradish-peroxidase (HRP)-conjugated goat anti-rabbit secondary 
antibody (Pierce, Thermo Fischer Scientific, Rockford, IL, USA) diluted 1:10,000 in blocking 
solution. Five washes in TBS-Tween were followed by detection of the enhanced 
chemiluminescent signal (Immobilon Western, Millipore Corporation, Billerica, MA, USA). 
Densitometry was carried out using the ImageJ software (National Institutes of Health, USA).  
Evaluation of Western blots  
 Densitometric values were plotted on graphs as the mean ± S.D. for four or five 
independent experiments. Significance of differences was determined using ANOVA testing 
applying Bonferroni corrections for multiple samples. P values ˂ 0.05 were considered to be 
significant. 
DNA fragmentation analysis  
Adherent and floating/dead cells alike were scraped into their culturing media and 
pelleted by centrifugation at 4 °C in 15 ml plastic tubes. After the removal of the supernatant 
the pellet was lysed in 0.5 ml ice-cold lysis buffer (5 mM Tris-HCl, 5 mM EDTA, 0.5 % 
Triton-X 100, pH 7.4) for 20 minutes on ice. The detergent-insoluble fraction was removed by 
centrifugation (at 40,000 x g for 30 minutes at 4 °C) and the lysate was deproteinized by two 
rounds of phenol and one round of chloroform extraction. DNA was precipitated by the 
addition of 1 ml absolute ethanol and 50 µl 3M Na-acetate to the 0.5 ml protein-free lysate 
and incubation at -20 °C overnight. The precipitated nucleic acid was collected by 
centrifugation (at 100,000 x g for 30 minutes at 4 °C). The pellet was washed in 0.5 ml of 70 
% ethanol, then vacuum-dried. The dry material was solubilized in 20 µl of Tris-EDTA (pH 
7.4) buffer and the contaminating RNA was digested with RNase A treatment. The remaining 
DNA fragments were resolved by electrophoresis in a 1.8% agarose gel and visualized for 
imaging by the addition of 100-fold diluted SYBR Gold nucleic acid dye (Molecular Probes, 
Eugene, OR, USA). 
Fluorescence microscopy 
Treatments were stopped by a quick rinse in 37 °C PBS (1.37 mM NaCl, 0.27 mM 
KCl, 0.43 mM Na2HPO4·7H2O, 0.14 mM KH2PO4, pH 7.4) followed by fixation in 4% 
paraformaldehyde in PBS, pH 7.4 for 1 hour at room temperature. Excess fixative was washed 
out in three changes of PBS, then three changes of TBS (50 mM Tris-HCl, pH 7.4, 150 mM 
NaCl). Blocking of nonspecific binding sites was carried out by incubation of the samples in 
5% nonfat dry milk in TBS at 4 ˚C for 1 hour under gentle rocking. The primary antibodies 
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TrkA (R&D Systems) and Hsp90 (Santa Cruz Biotechnology) were diluted 1:500 in the 
blocking solution and incubated with the specimens overnight at 4 ˚C under gentle rocking. 
Five washes in TBS followed. The fluorescent signal was generated by the addition of a Cy3-
conjugated donkey-anti-rabbit antibody (Jackson Immuno Research, Cambridgeshire, UK) 
diluted in the blocking solution 1:500. At this dilution rate the methodical control samples 
prepared from antigen-deficient (nnr5) cells (for anti-TrkA) or by the omission of the primary 
antibodies (for all samples) produced no immune signal using the applied microscope settings. 
Nuclei were counterstained with Hoechst 33342 (Calbiochem, La Jolla, CA, USA).  
Confocal images were generated using an Olympus FV-1000 laser scanning confocal 
system. Single optical sections from areas of interest were taken using a 40X phase objective. 
In the case of P-ERK1/2 immunocytochemistry the average intensity of pixels in the 
area of nuclei were determined using the ImageJ software (National Institutes of Health, 
USA), then normalized to background intensity and plotted on a graph. The significance of 
the differences was determined using ANOVA testing applying Bonferroni corrections for 
multiple samples. P values ˂ 0.05 were considered to be significant. 
 
Results 
 
Pilot experiments repeatedly confirmed that dimethyl-sulfoxyde (DMSO), the vehicle 
of the compounds geldanamycin and MG-132, had no effect on the examined parameters of 
the experiments at the concentrations applied (0.025 v/v % for single treatments and 0.05 v/v 
% when geldanamycin and MG-132 were applied in combination).  
 
1. The effect of geldanamycin on PC12 rat pheochromocytoma cells is time and dose 
dependent. 
PC12 cells have responded to geldanamycin in a dose- and time-dependent manner. In 
keeping with recent results of Toyomura et al. (2012) if treated with the higher dose 1.78 μM 
(1 µg/ml) of the antibiotic the cells responded with apoptosis already after 16 hours as shown 
by the activation of caspase-3 on our Western-blot. One tenth of this dose (0.178 μM) had to 
be present in the culture for at least 24 hours to produce initial signs of caspase-3 cleavage but 
proved to be safe and was not followed by programmed cell death if used only for 16 hours. 
These results have also been confirmed by DNA fragmentation analysis. 
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2. Geldanamycin reduces the level of TrkA. 
 Next we examined the expression level of the TrkA NGF receptor under our above 
tested, non-apoptotic experimental settings with geldanamycin. The treatment unable to elicit 
apoptosis led to a markedly reduced expression of TrkA protein in PC12 cultures as seen on 
our Western-blots. 
 
3. Inhibition of proteasome function partially restores TrkA protein in geldanamycin-
treated PC12 cells. 
 When the specific proteasome inhibitor compound MG-132 was applied together with 
geldanamycin the effect of the latter to reduce the amount of TrkA was substantially weaker 
as shown by our Western blot results. 
 
4. Dissociation of TrkA and Hsp90 upon geldanamycin treatment. 
Having seen the reduced level of TrkA upon inhibiting Hsp90 by geldanamycin we 
decided to examine the intracellular association of the high affinity NGF receptor and the 90 
kDa chaperone by means of co-immune precipitation. While TrkA and Hsp90 were found to 
co-precipitate in untreated PC12 cells, after geldanamycin treatment their interaction was no 
longer observable and it remained disrupted even if the proteasome inhibitor was added 
together with geldanamycin. The marked reduction in the amount of the associated chaperone 
was not due to its reduced overall levels as shown by Western blot of the lysates. 
 
5. Inhibition of the proteasome function can restore NGF-induced TrkA phosphorylation 
in geldanamycin-treated PC12 cells. 
 In order to evaluate if the TrkA protein saved by MG-132 from degradation was still 
responsive to NGF we performed Western blotting with an antibody specific to the 
phosphorylated form of TrkA following geldanamycin and MG-132 treatments. The NGF-
inducibility of TrkA phosphorylation effectively blocked by geldanamycin could successfully 
be restored by the simultaneous inhibition of the proteasome. In fact, NGF stimulation of 
TrkA phosphorylation appeared to be somewhat stronger in lysates derived from cells treated 
with both geldanamycin and MG132. This observation is in accordance with data reported by 
Song et al. (2009, 2011) about the effect of MG-132 on TrkA. 
 
 
10 
 
 
6. Reduced ERK 1 and 2 phosphorylation following geldanamycin treatment.  
Next by further Western blotting we examined if NGF activation of TrkA could 
successfully be transmitted onto downstream members of protein kinase cascades in cells 
treated with both geldanamycin and MG-132. The phosphorylation of ERK 1 and 2 as an easy 
measure of detecting NGF’s downstream effect revealed that the lower dose and shorter 
duration of geldanamycin treatment not able to initiate apoptosis, could already weaken the 
level of ERK 1 and 2 phosphorylation induced by NGF. 
 
7. Inhibition of the proteasome function restores the NGF-inducible ERK1/2 
phosphorylation in geldanamycin-treated PC12 cells. 
Western blots also shown that simultaneous addition of the proteasome inhibitor MG-
132 could restore the NGF-inducibility of ERK1/2 in geldanamycin-treated cultures when 
compared to treatments with geldanamycin and NGF only. The somewhat elevated baseline 
phosphorylation of ERK upon inhibition of the proteasome can be attributed to the ERK 
phosphorylation inducing ability of MG-132 itself. Reprobing the membrane for total ERK1/2 
excluded the possibility of the observed changes in ERK1/2 phosphorylation being due to 
loading differences of the lanes. 
 
8. Phosphorylation of Akt is inhibited following geldanamycin treatment.  
Not only the NGF activation of ERK1/2 but that of protein kinase B/Akt was also 
compromised in geldanamycin-treated PC12 cultures. The baseline phosphorylation of Akt 
was also reduced after geldanamycin treatment to barely detectable. (Western blot) 
 
9. Inhibition of the proteasome function does not restore NGF-inducible protein kinase 
B/Akt phosphorylation in geldanamycin-treated PC12 cells.  
Our Western blots have shown that that he proteasome inhibitor MG-132, when 
applied together with geldanamycin under the same conditions that could salvage the NGF 
activation of ERK1 and 2, could not restore activation of protein kinase B/Akt upon NGF 
treatment. Baseline Akt phosphorylation, however, was elevated after pretreatment with the 
proteasome inhibitor as also reported earlier by Moises et al. (2009).  
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10. The intracellular distribution of TrkA is altered in geldanamycin- and MG-132-treated 
PC12 cells (immunocytochemistry). 
The proteasome inhibitor MG-132, when applied together with geldanamycin, could 
efficiently save a substantial portion of TrkA protein as seen on Western blots. The 
intracellular localization of salvaged TrkA, nevertheless, was dramatically different when 
compared to the TrkA immunoreactivity pattern of untreated PC12 cells. In untreated cells a 
substantial portion of TrkA was in the immediate vicinity of the plasma. The TrkA signal of 
cells treated with the Hsp90 inhibitor geldanamycin was barely detectable at the level of 
individual cells. In cultures treated with both geldanamycin and the proteasome inhibitor MG-
132 the TrkA signal regained in strength but was no longer shifted towards the plasma 
membrane, instead it was evenly distributed throughout the entire cytoplasm. Proteasome 
inhibition alone had no effect on the intracellular pattern of TrkA immunoreactivity when 
compared to untreated controls. (The intracellular localization of p-TrkA, unfortunately, could 
not be determined, because the antibody used for Western blot was not suitable for 
immunocytochemical detection of the target protein as stated by the manufacturer and also 
supported by our repeatedly failed trials.) 
 
11. The intracellular distribution of Hsp90 is altered in geldanamycin- and MG-132-
treated PC12 cells (immunocytochemistry).  
Having seen the changes in the distribution of TrkA we decided to examine the 
intracellular localization of Hsp90, too. In untreated cells and upon geldanamycin treatment 
the Hsp90 immune signal had an even distribution predominantly over the cytoplasm. After 
combined treatment with geldanamycin and MG-132, however, Hsp90 was markedly shifted 
towards the periphery of the cytoplasm. Proteasome inhibition alone had no effect on the 
intracellular pattern of Hsp90 immunoreactivity when compared to untreated controls. The 
overall level of Hsp90 was not affected by MG-132 and/or geldanamycin treatments as shown 
by Western blot. 
 
12. The kinetics of ERK1/2 phosphorylation induced by the MG-132 proteasome inhibitor 
in PC12 cells. 
 The phosphorylation of ERK1/2 upon MG-132 treatment alone was further studied by 
our workgroup also inspired by Hashimoto et al. We first applied MG-132 for increasing 
periods of time and then analyzed ERK phosphorylation by Western-blot using an anti-
phospho-ERK1/2 antibody The increased phosphorylation of ERK1/2 compared to the 
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untreated control was already detectable after 15 minutes and it was found to be prolonged 
rising ot a peak at 6 hours of pretreatment. After 24 hours the level of activation was still 
higher than in the untreated cultures. The total ERK1/2 content of the different samples was 
detected on the same membranes and used for normalization during the densitometric 
analysis. 
 
13. The phosphorylated ERK1/2 is translocated into the nuclei of PC12 cells upon MG-132 
proteasome inhibitor treatment.  
 We studied the alteration of the intrcellular distribution of phospho-ERK1/2 after MG-
132 pretreatment by fluorescent immunocytochemistry. The weak immune signal was mostly 
cytoplasmic in untreated cultures. The 6 hours long treatment with the MG-132 proteasome 
inhibitor increased the amount of activated ERK1/2 in the nucleus and in the cytoplasm, 
similarly to the 3 hours long NGF treatment. This nuclear translocation and sustained 
activation of phospho-ERK1/2 confirms the observations of MG-132 inducing neurite growth 
in PC12 cells similarly to NGF. 
 
Discussion 
 
During our research we found that the treatment of wild type PC12 rat 
pheochromocytoma cells with geldanamycin leads to reduced levels of TrkA protein well 
before the onset of programmed cell death. Drug sensitivity of cell lines including PC12 cells 
may vary due to clonal differences, passage number and culturing conditions. The dose of 
geldanamycin used in our experiments was just a tenth of that inducing apoptosis in the 
experiments of others. Furthermore, our treatment time was also reduced by about one third. 
Despite of the milder treatment, the NGF stimulation of ERK1/2 and protein kinase B/Akt 
were both severely compromised under such conditions. 
The simultaneous treatment with the proteasome inhibitor MG-132 helped to keep the 
level of TrkA higher than that seen in the cultures treated with geldanamycin alone and it also 
rendered the phosphorylation of the receptor upon NGF stimulation again possible. NGF 
activation of TrkA in cultures treated with both geldanamycin and the proteasome inhibitor 
was in fact somewhat stronger than that seen in PC12 cells without pretreatment. The ability 
of the proteasome inhibitor MG-132 to potentiate the effect of NGF has been reported by 
Song et al. (2009, 2011). Nevertheless, the activating effect of NGF on TrkA could only be 
13 
 
further transmitted onto ERK1/2 but not towards protein kinase B/Akt in cultures pretreated 
with both geldanamycin and MG-132.  
The intracellular distribution of the TrkA immune signal in untreated PC12 cells was 
cytoplasmic, as expected, with a substantial portion of the immunoreactivity being strongly 
shifted towards the periphery of the cytoplasm into the immediate vicinity of the plasma 
membrane. According to the Western blot results the TrkA immune signal has become much 
weaker in the presence of geldanamycin but has regained strength if the proteasome inhibitor 
MG-132 was also present during treatment with the Hsp90 antagonist. Despite its regained 
intensity the original, membrane-associated fraction of the TrkA signal was not restored by 
MG-132 in geldanamycin-treated cells. This newly acquired intracellular position of TrkA 
raises the possibility that it might also have altered downstream signaling connections. 
Interestingly, the Hsp90 immunoreactivity showed a shift into the opposite direction, towards 
the membrane in cells treated with both geldanamycin and MG-132. Currently we can only 
speculate about the significance of this latter observation. One possibility could be that MG-
132, being a rather hydrophobic compound reaches preferentially the peripheral regions of the 
cytoplasm by diffusion. Here, it could lead to the accumulation of Hsp90’s protein partners 
compromised by geldanamycin but saved by MG-132 from the proteasome. The accumulation 
of these proteins might result in a compensatory shift of Hsp90 capacity in the same direction. 
The phenomenon will be worth further investigating. 
Pre-organized molecular complexes are known to increase the efficiency of 
intracellular signal transduction markedly. The altered intracellular localization of TrkA in 
cells treated with both geldanamycin and MG-132 raises the possibility that a substantial 
portion of TrkA may no longer be close enough to the plasma membrane to effectively 
stimulate all of its downstream cascades. Jullien et al. (2003) reported that gp140 TrkA is the 
only form of TrkA readily detectable at the PC12 cell surface. In their studies treatment by 
NGF produced a clearing of more than 70% of the receptor from the cell surface within 15 
minutes of treatment. With similar results Grimes et al. (1996) have found that 66% of the 
receptor initially labeled at the PC12 cell surface was found inside the cells after 20 minutes 
of NGF treatment. Currently we can’t tell exactly why the TrkA receptors saved by 
proteasome inhibition in geldanamycin-treated PC12 cells did not return to their membrane-
associated original location. There are several points at which inhibition of the proteasome 
could interfere with the regular and quite dynamic trafficking of TrkA. In experiments of 
Sommerfeld et al. (2000) the brain-derived neurotrophic factor (BDNF) receptor TrkB was 
downregulated following the binding of BDNF. This could be prevented by the inhibition of 
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the proteasome. TrkA is rapidly and transiently ubiquitinated upon addition of NGF and it has 
been shown that TrkA is deubiquitinated by proteasomes prior to degradation by lysosomes 
whereby the scaffold protein p62 acts as a shuttling protein in the internalization and transport 
of TrkA. The kinetics of receptor trafficking post-internalization occurs as a sequel from early 
into late endosome, then into multivesicular bodies and proteasomes, finally degradation in 
the lysosomes or, alternatively, TrkA can also return to the membrane from early endosomes 
through recycling endosomes. 
According to a study by Zhang et al. (2000) neuronal differentiation of PC12 cells is 
promoted by catalytically active Trk-s within endosomes in the cell interior. In contrast, 
survival responses are initiated by activated receptors at the cell surface where they 
orchestrate prolonged activation of protein kinase B/Akt. Thus, interaction between TrkA and 
intracellular signaling molecules are dictated by both phosphotyrosine residues of the 
activated receptors and by the intracellular location of the latter. The activated receptor 
subunits with their phosphorylated tyrosines build scaffolding for the assembly of a multi-
enzyme signaling complex. The altered intracellular distribution of TrkA could explain, at 
least from the viewpoint of protein localization, why its activation by NGF could not lead to 
subsequent phosphorylation of protein kinase B/Akt under such conditions.  
Our research group further analyzed the effects of MG-132 as we confirmed that the 
proteasome inhibitor, similarly to NGF, induces a prolonged ERK1/2 phosphorylation 
parallelly causing a nuclear translocation as well. This behavior of ERK leads to neurite 
growth and neural differentiation, it was therefore not surprising when MG-132 treatment also 
led to the appearance of cellular processes in these cell cultures. We studied further which 
elements of the NGF receptor-ERK cascade way are necessary for the described activation by 
paying special attention to the non-receptor tyrosine-protein kinase Src.  
Our experiments shed light on the fact that protein-protein interactions, the creation of 
multiprotein complexes, especially the formation of heteromultimers containing the Hsp90 is 
essential for signaling processes. We believe that our observations may help to better 
understand the mechanisms of action of geldanamycin and MG-132, two compounds with 
derivatives possessing strong human therapeutic potential.  
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